Abatacept therapy and safety management
- PMID: 22541956
- DOI: 10.1016/S1297-319X(12)70011-8
Abatacept therapy and safety management
Abstract
Objectives: To develop and/or update fact sheets about abatacept treatment, in order to assist physicians in the management of patients with inflammatory joint disease.
Methods: 1. selection by a committee of rheumatology experts of the main topics of interest for which fact sheets were desirable 2. identification and review of publications relevant to each topic 3. development and/or update of fact sheets based on three levels of evidence: evidence-based medicine, official recommendations, and expert opinion. The experts were rheumatologists and invited specialists in other fields (dermatologist, cardiologist, pediatric rheumatologist, endocrinologist, hematologist, immunologist, infectiologist), and they had extensive experience with the management of chronic inflammatory diseases, such as rheumatoid arthritis (RA). They were members of the CRI (Club Rhumatismes et Inflammation), a section of the French Rheumatology Society (Societe Francaise de Rhumatologie). Each fact sheet was revised by several experts and the overall process was coordinated by three experts.
Results: Several topics of major interest were selected: contraindications of abatacept treatment; management of adverse effects and concomitant diseases that may develop during abatacept treatment; and management of common situations such as pregnancy, surgery, patient older than 75 years of age, and patients with co-morbidities (such as dialysis, hemoglobinopathy, or splenectomy). After a review of the literature and discussion among experts, a consensus was developed about the content of the fact sheets presented here. These fact sheets focus on several points: 1. in RA, initiation and monitoring of the abatacept treatment, management of patients with specific past histories, and specific clinical situations such as pregnancy 2. diseases other than RA, such as juvenile idiopathic arthritis, spondylarthropathies, or autoimmune diseases (systemic lupus erythematosus and other systemic autoimmune diseases) 3. models of letters for informing the rheumatologist and general practitioner 4. patient information about the use of abatacept in RA 5. and data on the new abatacept formulation for subcutaneous administration (approved by the FDA in August 2011 for patients with moderate-to-severe RA).
Conclusion: These fact sheets built on evidence-based medicine and expert opinion will serve as a practical tool for assisting physicians who manage patients on abatacept. They will be available continuously on www.cri-net.com and will be updated at appropriate intervals.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Use of abatacept in rheumatoid arthritis.Swiss Med Wkly. 2012 May 11;142:w13581. doi: 10.4414/smw.2012.13581. eCollection 2012. Swiss Med Wkly. 2012. PMID: 22581564 Review.
-
TNF alpha antagonist therapy and safety monitoring.Joint Bone Spine. 2011 May;78 Suppl 1:15-185. doi: 10.1016/S1297-319X(11)70001-X. Joint Bone Spine. 2011. PMID: 21703545
-
Tocilizumab: therapy and safety management.Joint Bone Spine. 2010 Jun;77 Suppl 1:S3-100. doi: 10.1016/S1297-319X(10)70001-4. Epub 2010 Jun 17. Joint Bone Spine. 2010. PMID: 20610315
-
Abatacept therapy and safety management.Joint Bone Spine. 2009 May;76 Suppl 1:S3-S55. doi: 10.1016/S1297-319X(09)74520-8. Joint Bone Spine. 2009. PMID: 19560051 Review.
-
Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.Curr Med Res Opin. 2008 Aug;24(8):2283-94. doi: 10.1185/03007990802223129. Epub 2008 Jun 27. Curr Med Res Opin. 2008. PMID: 18590608 Review.
Cited by
-
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.Rheumatology (Oxford). 2023 Apr 3;62(4):e48-e88. doi: 10.1093/rheumatology/keac551. Rheumatology (Oxford). 2023. PMID: 36318966 Free PMC article. No abstract available.
-
Development and real-life use assessment of a self-management smartphone application for patients with inflammatory arthritis. A user-centred step-by-step approach.PLoS One. 2022 Sep 15;17(9):e0272235. doi: 10.1371/journal.pone.0272235. eCollection 2022. PLoS One. 2022. PMID: 36107954 Free PMC article.
-
Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics: a multicentre randomised clinical trial.RMD Open. 2022 Mar;8(1):e001828. doi: 10.1136/rmdopen-2021-001828. RMD Open. 2022. PMID: 35296528 Free PMC article. Clinical Trial.
-
Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road.Front Pharmacol. 2021 Feb 11;12:621247. doi: 10.3389/fphar.2021.621247. eCollection 2021. Front Pharmacol. 2021. PMID: 34122062 Free PMC article. Review.
-
Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation.Wien Klin Wochenschr. 2019 Jan;131(1-2):29-44. doi: 10.1007/s00508-019-1448-y. Epub 2019 Jan 14. Wien Klin Wochenschr. 2019. PMID: 30643992 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous